Migration of Implanon®

Journal of Family Planning and Reproductive Health Care

Volumn 32, Issue 3, 2006, Pages 157-159

  Ismail, Hanan ^a,d   Mansour, Diana ^b   Singh, Madan ^c  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

^d Central Family Planning Clinic   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETONOGESTREL; CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEMALE CONTRACEPTIVE DEVICE; FOLLOW UP; HEALTH CARE ORGANIZATION; HEALTH PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MEASUREMENT; MIGRATION; PROSPECTIVE STUDY; DRUG IMPLANT; FOREIGN BODY; UNITED KINGDOM;

ADOLESCENT; ADULT; CONTRACEPTIVE AGENTS, FEMALE; DRUG IMPLANTS; FEMALE; FOREIGN-BODY MIGRATION; GREAT BRITAIN; HUMANS; PROSPECTIVE STUDIES;

EID: 33746270524     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118906777888413     Document Type: Article

References (6)

1. Buckshee K, Chatterjee P, Dhall GI, Hazra MN, Kodkhany BS, Lalitha K. Phase III clinical trial with Norplant II (two covered rods): report on five years of use. Contraception 1993; 48: 120-132.
2. Oloto EJ, Bromham DR. Norplant removal: a review. Br J Fam Plann 1995; 21(Suppl.): 21-24.
3. Cozens NJ. Contraceptive implants: high-resolution ultrasonography facilitates removal (Letter). BMJ 1996; 313: 880.
4. Evans R, Holman R, Lindsay E. Migration of Implanon®: two case reports. J Fam Plann Reprod Health Care 2005; 31: 71-72.
5. Croxatto HB, Makarainen L. The pharmacodynamics and efficacy of Implanon. Contraception 1998; 58: 91S-97S.
6. Organon Laboratories Ltd. Implanon: Summary of Product Characteristics. December 2003. http://www.medicines.org.uk